

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Apolipoprotein A-IV/ApoA4 in direct ELISAs.
Source	Monoclonal Mouse IgG ₁ Clone # 988829
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived human Apolipoprotein A-IV/ApoA4 protein Glu21-Ser396 Accession # P06727
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Apolipoprotein A-IV (ApoA4) is a 45 kDa glycoprotein of the lipid transport system. Secreted in plasma, ApoA4 is a major component of high density lipoprotein (HDL) particles and chylomicrons, and is thought to act in intestinal lipid absorption. Levels of ApoA4 may influence HDL metabolism and modulate its effects on atherogenesis (1). ApoA4 synthesis in humans is mainly confined to the small intestine, while in mice and rats, production occurs in the liver as well (2). ApoA4 shares several structural characteristics with ApoA1 and other exchangeable apolipoproteins. The core domain of human ApoA4 contains thirteen 22-amino acid tandem repeats, and nine of which are predicted to be amphipathic α -helical repeats that are critical for lipid binding and self-association (3). The overall structure of a long rod-like dimer consisting of two 4-helix bundles stacked end-to-end in opposing orientations (4). Human ApoA4 is synthesized as a 396 amino acid (aa) precursor, from which a 20 aa N-terminal signal peptide is removed. Mature human ApoA4 shares 61% and 62% aa sequence identity with mouse and rat ApoA4, respectively.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc., and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.